Recent FDA Approval and Mechanisms of Talazoparib in Breast Cancer

This chapter examines the FDA's approval of talazoparib, a PARP inhibitor for breast cancer patients with BRCA mutations. It covers its mechanism of action, effectiveness compared to other treatments, and important clinical considerations.